Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.

Huang YS, Wen J, Wang S, Song Y, Zhou B, Zhang N, Meng H

Obesity surgery23 May 2026

PMID42174244DOI10.1007/s11695-026-08748-5PepBankPUB-42174244

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, early adjunctive semaglutide gave a larger %TWL at 12 months than surgery alone.
In plain wordsAfter sleeve gastrectomy for severe obesity, patients who also took semaglutide early lost more weight at 12 months than those with surgery alone.
Peptide
Semaglutide
Outcome
Decrease%TWL at 12 months
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Measurements
%TWL
−35.14%
semaglutide group
%TWL
−30.73%
control group
Source sentences
Summary
as reflected by a larger %TWL (-35.14 ± 6.88% vs. -30.73 ± 6.91%, P = 0.002)
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424401
02HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, early adjunctive semaglutide gave a higher %EWL at 12 months than surgery alone.
In plain wordsAfter sleeve gastrectomy for severe obesity, patients who also took semaglutide early lost more excess weight at 12 months than those with surgery alone.
Peptide
Semaglutide
Outcome
Increase%EWL at 12 months
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Measurements
%EWL
86.42%
semaglutide group
%EWL
76.87%
control group
Source sentences
Summary
a higher %EWL (86.42 ± 19.94% vs. 76.87 ± 22.95%, P = 0.026).
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424402
03HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, %TWL at 6 months was significantly greater with early adjunctive semaglutide than with surgery alone.
In plain wordsAfter sleeve gastrectomy for severe obesity, patients who also took semaglutide lost more weight at 6 months than those with surgery alone.
Peptide
Semaglutide
Outcome
Decrease%TWL at 6 months
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Measurements
%TWL
−29.74%
semaglutide group
%TWL
−26.32%
control group
Source sentences
Summary
Similarly, at 6 months postoperatively, %TWL was significantly greater in the treatment group (-29.74 ± 5.38% vs. -26.32 ± 4.10%, P < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424403
04HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, %EWL at 6 months did not differ significantly between the semaglutide and surgery-alone groups.
In plain wordsAfter sleeve gastrectomy for severe obesity, excess weight loss at 6 months did not differ significantly between patients with and without semaglutide.
Peptide
Semaglutide
Outcome
No significant change%EWL at 6 months
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
whereas no significant between-group difference in %EWL was observed at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424404
05HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, the distributions of %TWL and %EWL were more favorable with early adjunctive semaglutide than with surgery alone.
In plain wordsAfter sleeve gastrectomy for severe obesity, weight loss was spread more favorably in patients who also took semaglutide than in those with surgery alone.
Peptide
Semaglutide
Outcome
IncreaseDistributions of %TWL and %EWL
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
In addition, the distributions of %TWL and %EWL were more favorable in the treatment group.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424405
06HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, results were generally consistent after propensity score adjustment, but the between-group difference in %EWL distribution was not significant.
In plain wordsAfter sleeve gastrectomy for severe obesity, the semaglutide results mostly held after adjusting for baseline differences, except for the spread of excess weight loss.
Peptide
Semaglutide
Outcome
MixedWeight loss after propensity score adjustment
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
These results were generally consistent after propensity score adjustment for baseline confounders, although the between-group difference in %EWL distribution was not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424406
07HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, both groups showed comparable improvements in metabolic indicators from baseline.
In plain wordsAfter sleeve gastrectomy for severe obesity, metabolic measures improved by a similar amount with and without semaglutide.
Peptide
Semaglutide
Outcome
No significant changeMetabolic indicators
Study
n = 103
Comparator
Both groups from baseline
Analysis
Secondary
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
Both groups showed comparable improvements in metabolic indicators from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424407
08HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, exploratory analysis showed a greater increase in lean body mass percentage in the semaglutide group.
In plain wordsAfter sleeve gastrectomy for severe obesity, an exploratory analysis showed a larger rise in lean body mass percentage with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseLean body mass percentage
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
a greater increase in lean body mass percentage and a greater reduction in visceral fat area in the treatment group, although these body composition findings should be interpreted cautiously.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424408
09HumanNon-randomized trialEfficacy outcome
In patients with class II-III obesity after sleeve gastrectomy, exploratory analysis showed a greater reduction in visceral fat area in the semaglutide group.
In plain wordsAfter sleeve gastrectomy for severe obesity, an exploratory analysis showed a larger drop in belly fat area with semaglutide.
Peptide
Semaglutide
Outcome
DecreaseVisceral fat area
Study
n = 103
Comparator
Laparoscopic sleeve gastrectomy alone
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · from 1 to 6 months postoperativelyAs given in this study (human).
Source sentences
Summary
a greater reduction in visceral fat area in the treatment group, although these body composition findings should be interpreted cautiously.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.
Summary · context
Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.
Summary · context
A total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group.
Report a problemFND-4217424409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords